CGTX COGNITION THERAPEUTICS INC
P/E
--
Forward P/E
--
Price/Sales
--
Beta
1.8
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Cognition Therapeutics beat third quarter 2026 earnings estimates but missed on revenue and received Nasdaq notice
Cognition Therapeutics reported a net loss of $4.1 million for the third quarter 2026, driven by higher clinical trial activity for its lead candidate...
Cognition Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
For the third quarter of 2026, Cognition Therapeutics is expected to report a consensus EPS loss of $0.07 on revenue of $5.30 million, with the stock currently...